Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 17/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15871459 | 0.92 | PIK3C2B (0.67) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL15022648 | 0.90 | PIK3C2B (0.75) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CA | |
| SCHEMBL15022803 | 0.89 | PIK3C2B (0.63) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CA | |
| SCHEMBL15023773 | 0.88 | PIK3C2B (0.75) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CA | |
| SCHEMBL15023090 | 0.88 | PIK3C2B (0.83) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CA | |
| SCHEMBL15023471 | 0.86 | PIK3C2B (0.76) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL15435075 | 0.84 | PIK3C2B (0.78) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL1281722 | 0.82 | PIK3C2B (0.75) | PIK3C2BPIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL15022881 | 0.82 | PIK3C2B (0.68) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL15871496 | 0.81 | PIK3C2B (0.66) | PIK3C2BPIK3CBPIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778937-B2 | Benzimidazole boronic acid derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778937-B2 | Benzimidazole boronic acid derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778937-B2 | Benzimidazole boronic acid derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130157977-A1 | Benzimidazole Boronic Acid Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157977-A1 | Benzimidazole Boronic Acid Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157977-A1 | Benzimidazole Boronic Acid Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157977-A1 | Benzimidazole Boronic Acid Derivatives As PI3 Kinase Inhibitors | PI4KB, PI4KA, PIK3CB | PIK3C2B 7/4885PIK3CB 3/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.